For Secondary Cardioprevention, Can We “Bridge” the Gap Between Evidence and Practice?

A multifaceted intervention in Brazil improved prescription rates of guideline-recommended therapies, but clinical effects were less clear.

Although we have strong evidence for secondary prevention of cardiovascular disease through pharmacotherapy, prescription of these life-saving medications remains suboptimal in real-world settings. Researchers in the Brazilian Intervention to Increase Evidence Usage — Cardiovascular Prevention (BRIDGE-CP) study tested the effectiveness of a multifaceted quality-improvement (QI) intervention to increase prescription to statins, antiplatelet therapy, and either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (NCT02851732).

The investigators randomized 40 outpatient clinics to the intervention or usual care; the 1619 enrolled patients had established coronary or peripheral artery disease or history of ischemic stroke (…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy